Brief: Viracta Therapeutics Says FDA Cleared IND Application For Trial In EBV+ Solid Tumors

Viracta Therapeutics

21/07/2021 13:41

July 21 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR PHASE 1B/2 TRIAL IN EPSTEIN-BARR VIRUS-POSITIVE (EBV+) SOLID
TUMORS
    * VIRACTA THERAPEUTICS - INITIATION OF PHASE 1B/2 TRIAL IS
EXPECTED IN SECOND HALF OF 2021

Source text for Eikon:  ID:nPn29XGl6a 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))